Logo image of TCON

TRACON PHARMACEUTICALS INC (TCON) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TCON - US89237H3084 - Common Stock

1.43 USD
-0.02 (-1.38%)
Last: 6/27/2024, 7:53:15 PM
1.08 USD
-0.35 (-24.48%)
After Hours: 6/27/2024, 7:53:15 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to TCON. TCON was compared to 529 industry peers in the Biotechnology industry. While TCON seems to be doing ok healthwise, there are quite some concerns on its profitability. TCON has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TCON had positive earnings in the past year.
In the past year TCON had a positive cash flow from operations.
TCON had negative earnings in each of the past 5 years.
In the past 5 years TCON reported 4 times negative operating cash flow.
TCON Yearly Net Income VS EBIT VS OCF VS FCFTCON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

1.2 Ratios

TCON has a better Return On Assets (18.69%) than 99.13% of its industry peers.
Industry RankSector Rank
ROA 18.69%
ROE N/A
ROIC N/A
ROA(3y)-97.7%
ROA(5y)-92.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TCON Yearly ROA, ROE, ROICTCON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2K 4K 6K

1.3 Margins

Looking at the Profit Margin, with a value of 14.39%, TCON belongs to the top of the industry, outperforming 97.04% of the companies in the same industry.
The Operating Margin and Gross Margin are not available for TCON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 14.39%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCON Yearly Profit, Operating, Gross MarginsTCON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K

More info and screens

4

2. Health

2.1 Basic Checks

TCON does not have a ROIC to compare to the WACC, probably because it is not profitable.
TCON has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TCON has been increased compared to 5 years ago.
TCON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TCON Yearly Shares OutstandingTCON Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M
TCON Yearly Total Debt VS Total AssetsTCON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

TCON has an Altman-Z score of -36.21. This is a bad value and indicates that TCON is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TCON (-36.21) is worse than 93.03% of its industry peers.
There is no outstanding debt for TCON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0
Altman-Z -36.21
ROIC/WACCN/A
WACC74.74%
TCON Yearly LT Debt VS Equity VS FCFTCON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

TCON has a Current Ratio of 0.80. This is a bad value and indicates that TCON is not financially healthy enough and could expect problems in meeting its short term obligations.
TCON has a Current ratio of 0.80. This is amonst the worse of the industry: TCON underperforms 90.59% of its industry peers.
A Quick Ratio of 0.80 indicates that TCON may have some problems paying its short term obligations.
TCON has a Quick ratio of 0.80. This is amonst the worse of the industry: TCON underperforms 90.07% of its industry peers.
Industry RankSector Rank
Current Ratio 0.8
Quick Ratio 0.8
TCON Yearly Current Assets VS Current LiabilitesTCON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

TCON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 808.59%, which is quite impressive.
TCON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.05% yearly.
EPS 1Y (TTM)808.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-269.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y32.05%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TCON will show a very negative growth in Earnings Per Share. The EPS will decrease by -15.22% on average per year.
Based on estimates for the next years, TCON will show a very strong growth in Revenue. The Revenue will grow by 63.68% on average per year.
EPS Next Y-142.4%
EPS Next 2Y-51.36%
EPS Next 3Y-84.04%
EPS Next 5Y-15.22%
Revenue Next Year-100%
Revenue Next 2Y-66.67%
Revenue Next 3Y32.08%
Revenue Next 5Y63.68%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TCON Yearly Revenue VS EstimatesTCON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2021 2023 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
TCON Yearly EPS VS EstimatesTCON Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 10 -10 -20 -30 -40

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

TCON is valuated cheaply with a Price/Earnings ratio of 0.16.
Based on the Price/Earnings ratio, TCON is valued cheaper than 100.00% of the companies in the same industry.
When comparing the Price/Earnings ratio of TCON to the average of the S&P500 Index (26.55), we can say TCON is valued rather cheaply.
TCON is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 0.16
Fwd PE N/A
TCON Price Earnings VS Forward Price EarningsTCON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of TCON indicates a rather cheap valuation: TCON is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 0.62
EV/EBITDA N/A
TCON Per share dataTCON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as TCON's earnings are expected to decrease with -84.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-51.36%
EPS Next 3Y-84.04%

More info and screens

0

5. Dividend

5.1 Amount

TCON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRACON PHARMACEUTICALS INC

NASDAQ:TCON (6/27/2024, 7:53:15 PM)

After market: 1.08 -0.35 (-24.48%)

1.43

-0.02 (-1.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2024-05-14/amc
Earnings (Next)08-12 2024-08-12/amc
Inst Owners9.71%
Inst Owner Change0%
Ins Owners214.98%
Ins Owner Change0%
Market Cap3.83M
Revenue(TTM)12.14M
Net Income(TTM)1.75M
Analysts80
Price Target31.11 (2075.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)51.34%
Min EPS beat(2)-9.57%
Max EPS beat(2)112.26%
EPS beat(4)3
Avg EPS beat(4)238.94%
Min EPS beat(4)-9.57%
Max EPS beat(4)537.41%
EPS beat(8)4
Avg EPS beat(8)115.22%
EPS beat(12)4
Avg EPS beat(12)66.7%
EPS beat(16)7
Avg EPS beat(16)54.23%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)771.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2457.58%
EPS NY rev (1m)0%
EPS NY rev (3m)-943.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.16
Fwd PE N/A
P/S 0.32
P/FCF 0.62
P/OCF 0.62
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)9.07
EY634.27%
EPS(NY)-2.92
Fwd EYN/A
FCF(TTM)2.29
FCFY160.11%
OCF(TTM)2.29
OCFY160.11%
SpS4.53
BVpS-0.66
TBVpS-0.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 18.69%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 14.39%
GM N/A
FCFM 50.52%
ROA(3y)-97.7%
ROA(5y)-92.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover1.3
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 351.03%
Current Ratio 0.8
Quick Ratio 0.8
Altman-Z -36.21
F-Score8
WACC74.74%
ROIC/WACCN/A
Cap/Depr(3y)149.7%
Cap/Depr(5y)98.15%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)808.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-269.44%
EPS Next Y-142.4%
EPS Next 2Y-51.36%
EPS Next 3Y-84.04%
EPS Next 5Y-15.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y32.05%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-66.67%
Revenue Next 3Y32.08%
Revenue Next 5Y63.68%
EBIT growth 1Y89.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y125.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y125.09%
OCF growth 3YN/A
OCF growth 5YN/A

TRACON PHARMACEUTICALS INC / TCON FAQ

Can you provide the ChartMill fundamental rating for TRACON PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 4 / 10 to TCON.


Can you provide the valuation status for TRACON PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 4 / 10 to TRACON PHARMACEUTICALS INC (TCON). This can be considered as Fairly Valued.


How profitable is TRACON PHARMACEUTICALS INC (TCON) stock?

TRACON PHARMACEUTICALS INC (TCON) has a profitability rating of 2 / 10.


What are the PE and PB ratios of TRACON PHARMACEUTICALS INC (TCON) stock?

The Price/Earnings (PE) ratio for TRACON PHARMACEUTICALS INC (TCON) is 0.16 and the Price/Book (PB) ratio is -2.18.